Valuation: Cerus Corporation

Market Cap 615M 541M 503M 462M 868M 58.99B 880M 5.98B 2.34B 29.13B 2.31B 2.26B 101B P/E 2026 *
-92.1x
P/E 2027 * -922x
Enterprise Value 615M 541M 503M 462M 868M 58.99B 880M 5.98B 2.34B 29.13B 2.31B 2.26B 101B EV / Sales 2026 *
2.58x
EV / Sales 2027 * 2.37x
Free-Float
96.31%
Yield 2026 *
-
Yield 2027 * -
1 day+4.78%
1 week-2.54%
Current month+5.14%
1 month+5.14%
3 months+55.05%
6 months+23.29%
Current year+49.03%
1 week 2.81
Extreme 2.8098
3.16
1 month 2.78
Extreme 2.78
3.47
Current year 1.62
Extreme 1.62
3.47
1 year 1.15
Extreme 1.15
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 01/07/2026
Chief Tech/Sci/R&D Officer 82 01/07/2015
Director of Finance/CFO 54 04/05/2009
Director TitleAgeSince
Chairman 59 16/03/2026
Director/Board Member 72 24/03/2014
Director/Board Member 51 01/07/2026
Date Insider Type Main position Quantity % Market Cap.
7/16/26 A Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 A Free

Chief Executive Officer

924,215 0.4613%
6/30/26 A Free

Chief Financial Officer

-97,276 0.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+4.78%-2.54%+120.86%+9.25% 615M
+1.97%+5.51%-16.55%+19.41% 129B
+0.45%+3.69%-0.43%-1.89% 13.01B
-1.09%-2.28%+61.09%+95.26% 8.92B
+5.94%+2.18%-45.47%-69.36% 4.65B
+0.75%-.--%-.--%+33.92% 3.63B
+2.16%-1.57%+0.47%+40.11% 2.68B
+3.09%-0.25%-25.21%-33.80% 1.63B
+4.51%+5.25%+2.58%-55.84% 1.63B
+1.49%-2.72%-19.16%-26.12% 1.61B
Average +2.46%+1.01%+7.82%+1.09% 16.75B
Weighted average by Cap. +2.27%+2.71%-10.75%+18.25%

Financials

2026 *2027 *
Net sales 238M 209M 195M 179M 336M 22.84B 340M 2.32B 905M 11.28B 894M 875M 38.97B 260M 228M 213M 195M 367M 24.92B 372M 2.53B 987M 12.3B 975M 954M 42.53B
Net income -6.24M -5.48M -5.1M -4.69M -8.8M -598M -8.92M -60.67M -23.7M -295M -23.42M -22.91M -1.02B -479K -421K -392K -360K -676K -45.97M -685K -4.66M -1.82M -22.7M -1.8M -1.76M -78.45M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
27/07/26 $3.070 +4.78% 1,655,123
24/07/26 $2.930 +2.09% 2,510,839
23/07/26 $2.870 -4.97% 2,535,678
22/07/26 $3.020 -3.21% 2,186,377
21/07/26 $3.120 -0.95% 2,849,612
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.070USD
Average target price
4.667USD
Spread / Average Target
+52.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock